newsfilter
← Earnings
Earnings Releases·

Instil Bio — Third Quarter 2026 Earnings Summary

  • Net loss narrowed significantly to $4.2 million ($0.62/share) for Q3 2026 from $13.6 million ($2.01/share) in 2025, with the nine-month loss decreasing to $13.0 million ($1.92/share) from $63.5 million ($9.58/share) in 2025.
  • Operating expenses were sharply reduced, with R&D dropping to $0.2 million in Q3 2026 from $9.1 million in 2025, while total cash and investments declined to $67.1 million as of September 30, 2026.
  • Management confirmed that the current cash position is sufficient to fund operations through 2027 and outlined a strategy to build a portfolio of asset-focused development subsidiaries via internal development or in-licensing.
  • Prior-period financial data for 2025 was corrected to reflect errors regarding property taxes and tenant reimbursements, though these adjustments were not material to previously issued statements.
Company
INSTIL BIO INC
Sector
Healthcare
Industry
Biotechnology